EUVIMEDEUVIMED entdecken
Crossref

Low Total IgE Predicts Non-Response to Omalizumab in Chronic Spontaneous Urticaria: A 10-Year Real-Life Study

Zeynep Yegin Katran, İsmet Bulut, Andaç Salman

International Archives of Allergy and Immunology · 2025

DOI: 10.1159/000548107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2025. Verfasst von Zeynep Yegin Katran und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Immunology, Süreyyapasa Training and Research Hospital, University of Health Sciences, Istanbul, Turkey, zynpyegin@hotmail.…. Hauptthemen laut MEDLINE: Omalizumab, Immunoglobulin E, Chronic Urticaria, Anti-Allergic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Omalizumab is an effective add-on therapy for chronic spontaneous urticaria (CSU) refractory to antihistamines. However, biomarkers predicting treatment response remain unclear. This 10-year real-life, retrospective study aimed to assess the efficacy and safety of omalizumab in CSU and to identify predictors of treatment response, particularly focusing on total IgE levels.

Methods

We included 221 adult CSU patients treated with omalizumab between 2015 and 2024. Clinical response was evaluated using Urticaria Activity Score over 7 days (UAS7) and Urticaria Control Test (UCT). Treatment response was categorized as rapid, late, or non-response. Laboratory parameters, including total IgE, eosinophils, and thyroid autoantibodies, were analysed in relation to treatment outcomes.

Results

Omalizumab provided rapid or late responses in 98.2% of patients, with significant reductions in UAS7 and improvements in UCT scores over time. Only 1.8% were non-responders. A total IgE level ≤12.5 IU/mL was identified as a strong predictor of non-response (AUC: 0.903), with 75.0% sensitivity and 96.7% specificity. Multivariate logistic regression revealed that lower total IgE levels independently predicted non-response (OR: 0.032, p = 0.031).

Conclusion

Omalizumab is effective and safe in real-life CSU management, even among patients with comorbidities such as autoimmune diseases and malignancies. Low total IgE levels may serve as a reliable biomarker for predicting non-response and guiding individualized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabImmunoglobulin EChronic UrticariaAnti-Allergic AgentsHumansFemaleMaleAdultMiddle AgedRetrospective StudiesTreatment OutcomeBiomarkers

Stichwörter der Autor:innen

BiomarkerChronic spontaneous urticariaOmalizumabTotal IgETreatment response

Substanzen

OmalizumabImmunoglobulin EAnti-Allergic AgentsBiomarkers

Autor:innen und Institutionen

  • Department of Allergy and Immunology, Süreyyapasa Training and Research Hospital, University of Health Sciences, Istanbul, Turkey, zynpyegin@hotmail.com.
  • Department of Allergy and Immunology, Süreyyapasa Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
  • Department of Dermatology, Acıbadem Mehmet Ali Aydınlar University School of Medicine, Acıbadem Healthcare Group, Altunizade Hospital, Istanbul, Turkey.

Zitieren

APA

Yegin Katran, Z., Bulut, İ., & Salman, A. (2025). Low Total IgE Predicts Non-Response to Omalizumab in Chronic Spontaneous Urticaria: A 10-Year Real-Life Study. International Archives of Allergy and Immunology. https://doi.org/10.1159/000548107

Vancouver

Yegin Katran Z, Bulut İ, Salman A. Low Total IgE Predicts Non-Response to Omalizumab in Chronic Spontaneous Urticaria: A 10-Year Real-Life Study. International Archives of Allergy and Immunology. 2025. doi:10.1159/000548107

BibTeX
@article{YeginKatran2025,
  author = {Yegin Katran, Zeynep and Bulut, İsmet and Salman, Andaç},
  title = {Low Total IgE Predicts Non-Response to Omalizumab in Chronic Spontaneous Urticaria: A 10-Year Real-Life Study},
  journal = {International Archives of Allergy and Immunology},
  year = {2025},
  doi = {10.1159/000548107}
}
Kostenlos starten →